Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
about
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alphaMonitoring the effect of belinostat in solid tumors by H4 acetylationTruncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphomaPhase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Orchestrating epigenetic roles targeting ocular tumorsBelinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective reviewNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyDimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugTrichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanateThe sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activityThe novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoSynergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells.Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.Vorinostat in solid and hematologic malignanciesUpdate on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.Differentiation therapy of leukemia: 3 decades of development.Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivoThe clinical development of histone deacetylase inhibitors as targeted anticancer drugs.The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cellsA phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemiaCombination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell linesThe Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Histone deacetylase inhibitors in Hodgkin lymphoma.Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).Dietary manipulation of histone structure and function.Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancerTargeting inflammation in heart failure with histone deacetylase inhibitors.The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.
P2860
Q24308024-2A386095-04A2-4F6D-8637-2DB781F2CE7CQ24644030-B691205E-5A5D-4F3A-A142-7E2F9672221BQ24655119-EA6316DE-A153-45F6-A136-0DC6F96D4B8CQ24681480-54D973A2-3382-49A2-A17B-9AE20D861666Q26751251-B8815DA5-2C47-456C-8ED8-7438CDDFEA0AQ26796449-2A0A5A49-992D-42DB-9204-2160A457B60CQ27304386-DED79AC7-A1E5-4C7A-86C3-5AF21B3603E8Q28082536-DC29BD33-A671-425F-80CB-35617403D3F4Q28282479-2F5BC817-7192-47C9-9DA2-9FBE058924C4Q28289793-4E7DCD56-B87C-4C9D-84D5-DF7C873CCA2AQ28383320-7701C302-07C2-47D5-83AC-C55742A609E5Q28487756-0FAC9C9E-D733-453F-B923-AA23C8EBA936Q28751751-C2BC199D-BDF1-4064-8A31-B3BC5F2ADD17Q30541284-749FC523-C977-4BBA-9CD9-2D1C0D61B7EFQ33375694-38FD5DE8-55AC-47E9-9A9F-0DECD7EFD6F4Q33385544-6D32CE5C-9837-4CC8-AB05-BB15D88A9C78Q33385966-9763B7A7-9AEB-427C-A72C-D9B1B1873E28Q33394863-4BCD37AB-7C14-49C0-B13D-65376F77F2C6Q33400756-7680BD7F-8535-4787-A4B0-60C56D5CCE51Q33409795-41C853F1-F903-4817-AEB8-93E2550E889AQ33423816-EB2078CA-1637-4A59-AF97-43E087DE325CQ33431711-49B5B403-E463-4870-A8CC-C42C9948E5A7Q33621141-C6769587-9E22-46FD-A027-80A70E98E7A1Q33745943-7931A928-4873-41DC-8322-7B707DCEF5E5Q33829390-41F627BA-C391-4BCC-A821-9352E6516BE6Q33952785-EB6B4AF0-FED4-413F-8E91-ADAF56479414Q34014818-560E0375-BCD4-47F9-88DC-5559A9B7A9E8Q34024557-A796405E-D07F-4FEE-9A86-21F15070DB82Q34240314-798558C8-9DBC-4DD1-8655-D67A972C8D68Q34414440-E74B74DF-09DF-4EBF-BDF8-71F8C9B12731Q34414452-65CBAFD5-6692-4760-8BBF-2530C54728FFQ34629026-2613298A-3256-479D-9620-B3450D0195E2Q34632964-C440A8C6-7328-4F7F-8356-DC939632C441Q34725589-81C70AF6-2D44-4B3F-9E5A-78BC6B27D983Q34898711-12747C58-8277-4113-B301-37A37E40C5AFQ35005604-673B4A60-396A-4D90-876C-822E4451A47FQ35016934-028B5FCB-F169-4D0C-A0AF-A3657EBE3386Q35016989-A0E74ABA-8B1C-4B45-BDFC-112BAF8A299AQ35017018-2093A567-C33D-4B38-B78E-520716C7B2FEQ35026864-1264F58E-AB42-4916-8150-DEA55E583503
P2860
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Clinical experience with intra ...... nced hematologic malignancies.
@ast
Clinical experience with intra ...... nced hematologic malignancies.
@en
type
label
Clinical experience with intra ...... nced hematologic malignancies.
@ast
Clinical experience with intra ...... nced hematologic malignancies.
@en
prefLabel
Clinical experience with intra ...... nced hematologic malignancies.
@ast
Clinical experience with intra ...... nced hematologic malignancies.
@en
P2093
P356
P1476
Clinical experience with intra ...... nced hematologic malignancies.
@en
P2093
Barbara MacGregor-Cortelli
Carol Portlock
Craig Moskowitz
Lawrence Schwartz
Mark L Heaney
Owen A O'Connor
Paul Marks
Robert Willim
Stacie Richardson
Stanley Frankel
P304
P356
10.1200/JCO.2005.01.9679
P407
P577
2005-12-05T00:00:00Z